RxDoctor Payments Data

Shelby Raiser, DO

Family Medicine · Thornville, OHNPI 1396725271

Payments from drug & device makers

$4,577in general payments, 2019–2025

Across 316 payments — averaging $14.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$689
  • AstraZeneca$523
  • Amgen$518
  • Novo Nordisk$398
  • Pfizer$386
  • Novartis$201
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,555100%
  • Education$60%
  • Entertainment$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,577 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$49,713
Medicare patients
114
Services billed
758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$114,292
EliquisApixaban55$59,846
Repatha SureclickEvolocumab51$46,431
MounjaroTirzepatide21$28,794
JanuviaSitagliptin Phosphate19$26,685
RybelsusSemaglutide14$26,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$17,865
Breo ElliptaFluticasone/Vilanterol16$10,857
Aimovig AutoinjectorErenumab-Aooe15$10,567
MyrbetriqMirabegron12$9,941
Tresiba Flextouch U-100Insulin Degludec15$6,985
VascepaIcosapent Ethyl14$6,822
Praluent PenAlirocumab12$5,965
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,708
Albuterol Sulfate HfaAlbuterol Sulfate83$3,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$398$140,46069 claims
PfizerEliquis$386$59,84655 claims
Lilly USA, LLCMounjaro$123$28,79421 claims
GSKTrelegy Ellipta, Breo Ellipta$103$28,72330 claims
MerckJanuvia$169$26,68519 claims
Astellas Pharma US IncMyrbetriq$131$9,94112 claims
Boehringer IngelheimStiolto Respimat$34$5,70812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Thornville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →